CASAMENTO CHARLES J — SEC insider filings
SEC reporting owner CIK 1117167. 48 insider filings on record with FilingPulse; latest filed 2026-11-10.
Transaction summary — filings shown
Covers all 48 filings on record, filed 2020-08-19 to 2026-11-10. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 13,000 shares, $33,280 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 31 legs across 16 filings — 146,318 shares, $7,252,631 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 48.
- Largest priced transaction: sale of 33,956 shares @ $67.11 ($2,278,797) in Eton Pharmaceuticals, Inc., filed 2026-11-10.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Eton Pharmaceuticals, Inc. (ETON) | Director | 8 | — | 5 legs · 80,555 sh · $5,345,072 | 16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | Director | 27 | 1 leg · 13,000 sh · $33,280 | 24 legs · 59,700 sh · $1,905,739 | 21 |
| First Wave BioPharma, Inc. (FWBI) | Director | 6 | — | 2 legs · 6,063 sh · $1,820 | 4 |
| PaxMedica, Inc. (PXMD) | Director | 5 | — | — | 5 |
| GT Biopharma, Inc. (GTBP) | Director | 2 | — | — | 2 |
Insider filings — CASAMENTO CHARLES J
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-10 | 4 | Eton Pharmaceuticals, Inc. (ETON) | Option exercise (M): 12,500 @ $7.31 · Option exercise (M): 27,400 @ $3.58 · Option exercise (M): 19,655 @ $8.61 · Option exercise (M): 21,000 @ $3.78 · Sale (S): 6,380 @ $64.33 · Sale (S): 14,715 @ $65.32 · +7 more | EDGAR |
| 2026-08-04 | 4 | Eton Pharmaceuticals, Inc. (ETON) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-01-14 | 4 | Eton Pharmaceuticals, Inc. (ETON) | Grant/award (A): 12,196 (derivative) @ $0 · Grant/award (A): 7,757 (derivative) @ $0 | EDGAR |
| 2025-12-16 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Grant/award (A): 164,000 (derivative) @ $0 | EDGAR |
| 2025-09-08 | 4 | GT Biopharma, Inc. (GTBP) | Grant/award (A): 62,500 (derivative) @ $0 | EDGAR |
| 2025-06-30 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Eton Pharmaceuticals, Inc. (ETON) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-10-23 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Gift (G): 13,000 @ $0 | EDGAR |
| 2024-09-11 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Purchase (P): 13,000 @ $2.56 | EDGAR |
| 2024-05-29 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Grant/award (A): 20,976 (derivative) @ $0 · Other (J): 20,976 (derivative) @ $0 | EDGAR |
| 2024-03-14 | 4 | PaxMedica, Inc. (PXMD) | Tax withholding (F): 992 @ $0.69 | EDGAR |
| 2024-02-15 | 4 | Eton Pharmaceuticals, Inc. (ETON) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | PaxMedica, Inc. (PXMD) | Tax withholding (F): 97 @ $0.76 | EDGAR |
| 2024-01-04 | 4 | First Wave BioPharma, Inc. (FWBI) | Grant/award (A): 19,633 @ $0 | EDGAR |
| 2023-12-19 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Grant/award (A): 31,522 (derivative) @ $0 | EDGAR |
| 2023-10-04 | 4 | PaxMedica, Inc. (PXMD) | Tax withholding (F): 6,536 @ $0.29 | EDGAR |
| 2023-09-18 | 4 | First Wave BioPharma, Inc. (FWBI) | Sale (S): 10 @ $0.43 | EDGAR |
| 2023-09-05 | 4 | First Wave BioPharma, Inc. (FWBI) | Sale (S): 6,053 @ $0.30 | EDGAR |
| 2023-06-21 | 4 | GT Biopharma, Inc. (GTBP) | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2023-05-30 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Grant/award (A): 92,958 (derivative) @ $0 | EDGAR |
| 2023-04-14 | 4 | PaxMedica, Inc. (PXMD) | Grant/award (A): 14,000 @ $0 | EDGAR |
| 2023-03-03 | 4 | Eton Pharmaceuticals, Inc. (ETON) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2023-01-05 | 4 | First Wave BioPharma, Inc. (FWBI) | Grant/award (A): 84,745 @ $0 | EDGAR |
| 2022-12-20 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Grant/award (A): 57,042 (derivative) @ $0 | EDGAR |
| 2022-10-04 | 4 | PaxMedica, Inc. (PXMD) | Grant/award (A): 51,583 @ $0 | EDGAR |
| 2022-05-26 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Grant/award (A): 91,235 (derivative) @ $0 | EDGAR |
| 2022-04-05 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Option exercise (M): 19,800 @ $3.24 · Sale (S): 3,300 @ $29 · Sale (S): 3,300 @ $29 · Sale (S): 3,300 @ $29 · Sale (S): 3,300 @ $29 · Sale (S): 3,300 @ $29 · +2 more | EDGAR |
| 2022-02-28 | 4 | Eton Pharmaceuticals, Inc. (ETON) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2022-01-03 | 4 | First Wave BioPharma, Inc. (FWBI) | Grant/award (A): 34,482 (derivative) @ $0 | EDGAR |
| 2021-12-21 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Grant/award (A): 58,765 (derivative) @ $0 | EDGAR |
| 2021-09-24 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Option exercise (M): 10,000 @ $4.60 · Sale (S): 1,900 @ $29 · Sale (S): 3,300 @ $29 · Sale (S): 1,400 @ $29 · Option exercise (M): 1,900 (derivative) @ $0 | EDGAR |
| 2021-08-19 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Option exercise (M): 10,000 @ $4.60 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2021-07-16 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Sale (S): 2,136 @ $31.03 · Sale (S): 1,164 @ $32.49 | EDGAR |
| 2021-06-22 | 4/A | RELMADA THERAPEUTICS, INC. (RLMD) | Holdings only — no transactions reported | EDGAR |
| 2021-06-02 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Sale (S): 520 @ $34.08 · Sale (S): 2,480 @ $33.19 | EDGAR |
| 2021-05-05 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Sale (S): 3,000 @ $38.22 | EDGAR |
| 2021-05-05 | 4 | Eton Pharmaceuticals, Inc. (ETON) | Grant/award (A): 19,655 (derivative) @ $0 | EDGAR |
| 2021-04-05 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Sale (S): 1,309 @ $35.93 · Sale (S): 1,691 @ $35.04 | EDGAR |
| 2021-03-02 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Sale (S): 3,000 @ $33.87 | EDGAR |
| 2021-02-02 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Sale (S): 1,337 @ $33.30 · Sale (S): 1,663 @ $33.90 | EDGAR |
| 2021-01-11 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2021-01-06 | 4 | AzurRx BioPharma, Inc. (AZRX) | Grant/award (A): 41,237 (derivative) @ $0 | EDGAR |
| 2021-01-05 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Sale (S): 3,000 @ $32.11 | EDGAR |
| 2020-12-02 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Gift (G): 21,223 @ $0 · Sale (S): 3,000 @ $35.74 | EDGAR |
| 2020-11-03 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Sale (S): 3,000 @ $30.29 | EDGAR |
| 2020-10-02 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Sale (S): 3,000 @ $37.99 | EDGAR |
| 2020-09-02 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Sale (S): 3,000 @ $34.74 | EDGAR |
| 2020-08-19 | 4 | RELMADA THERAPEUTICS, INC. (RLMD) | Option exercise (M): 26,362 @ $3.24 · Tax withholding (F): 2,189 @ $39.03 · Option exercise (M): 26,362 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-18 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1117167 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs